Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1067–1071. doi: 10.1038/bjc.1997.509

Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

Y Ando 1, H Minami 1, H Saka 1, M Ando 1, S Sakai 1, K Shimokata 1
PMCID: PMC2228094  PMID: 9376268

Abstract

Carboplatin clearance depends on the glomerular filtration rate (GFR), and Calvert's formula is frequently used to achieve a target area under the time vs concentration curve (mg ml(-1) min). Creatinine clearance is a substitute for GFR when creatinine values are determined by the Jaffé method, which is being replaced by the enzymatic method. When the enzymatic method is used, the corresponding creatinine clearance theoretically exceeds GFR, and the use of creatinine clearance as GFR in Calvert's formula results, accordingly, in overdosing of carboplatin. In this study, we have established a model for adjusting the creatinine clearance to offset this bias based on a relationship between creatinine values measured by the Jaffé method and by the enzymatic method: adjusted creatinine clearance (ml min(-1)) = creatinine clearance (ml min(-1)) x [serum creatinine (mg dl(-1))]/[serum creatinine (mg dl(-1)) + 0.2]. Subsequently, we validated this model using the data from 35 lung cancer patients. Estimated clearances of carboplatin with the original equation [creatinine clearance + 25] were systematically higher than observed clearances [mean prediction error (MPE) +/- standard error (s.e.) = 26 +/- 5%]. This positive bias was corrected by the adjustment (MPE +/- s.e. = 5 +/- 4%). When the enzymatic method is used, the adjusted creatinine clearance should be used in Calvert's formula.

Full text

PDF
1067

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando Y., Minami H., Saka H., Ando M., Sugiura S., Sakai S., Shimokata K. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. Jpn J Cancer Res. 1997 May;88(5):517–521. doi: 10.1111/j.1349-7006.1997.tb00412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  3. Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., Roché H., Houin G., Bugat R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995 Apr 19;87(8):573–580. doi: 10.1093/jnci/87.8.573. [DOI] [PubMed] [Google Scholar]
  4. Crocker H., Shephard M. D., White G. H. Evaluation of an enzymatic method for determining creatinine in plasma. J Clin Pathol. 1988 May;41(5):576–581. doi: 10.1136/jcp.41.5.576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DOOLAN P. D., ALPEN E. L., THEIL G. B. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med. 1962 Jan;32:65–79. doi: 10.1016/0002-9343(62)90183-3. [DOI] [PubMed] [Google Scholar]
  6. Daugaard G., Rossing N., Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21(2):163–167. doi: 10.1007/BF00257365. [DOI] [PubMed] [Google Scholar]
  7. Fabiny D. L., Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the CentrifiChem. Clin Chem. 1971 Aug;17(8):696–700. [PubMed] [Google Scholar]
  8. Green J. A., Smith K. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide. Cancer Chemother Pharmacol. 1990;26 (Suppl):S22–S25. doi: 10.1007/BF00685411. [DOI] [PubMed] [Google Scholar]
  9. Guder W. G., Hoffmann G. E., Hubbuch A., Poppe W. A., Siedel J., Price C. P. Multicentre evaluation of an enzymatic method for creatinine determination using a sensitive colour reagent. J Clin Chem Clin Biochem. 1986 Nov;24(11):889–902. [PubMed] [Google Scholar]
  10. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  11. Jodrell D. I., Egorin M. J., Canetta R. M., Langenberg P., Goldbloom E. P., Burroughs J. N., Goodlow J. L., Tan S., Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992 Apr;10(4):520–528. doi: 10.1200/JCO.1992.10.4.520. [DOI] [PubMed] [Google Scholar]
  12. Kassirer J. P. Clinical evaluation of kidney function--glomerular function. N Engl J Med. 1971 Aug 12;285(7):385–389. doi: 10.1056/NEJM197108122850706. [DOI] [PubMed] [Google Scholar]
  13. Langer C. J., Leighton J. C., Comis R. L., O'Dwyer P. J., McAleer C. A., Bonjo C. A., Engstrom P. F., Litwin S., Ozols R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995 Aug;13(8):1860–1870. doi: 10.1200/JCO.1995.13.8.1860. [DOI] [PubMed] [Google Scholar]
  14. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin Chim Acta. 1972 Oct;41:209–217. doi: 10.1016/0009-8981(72)90513-x. [DOI] [PubMed] [Google Scholar]
  15. LeRoy A. F., Wehling M. L., Sponseller H. L., Friauf W. S., Solomon R. E., Dedrick R. L., Litterst C. L., Gram T. E., Guarino A. M., Becker D. A. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 1977 Oct;18(2):184–191. doi: 10.1016/0006-2944(77)90089-8. [DOI] [PubMed] [Google Scholar]
  16. Lustgarten J. A., Wenk R. E. Simple, rapid, kinetic method for serum creatinine measurement. Clin Chem. 1972 Nov;18(11):1419–1422. [PubMed] [Google Scholar]
  17. Reyno L. M., Egorin M. J., Canetta R. M., Jodrell D. I., Swenerton K. D., Pater J. L., Burroughs J. N., Novak M. J., Sridhara R. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol. 1993 Jun;11(6):1156–1164. doi: 10.1200/JCO.1993.11.6.1156. [DOI] [PubMed] [Google Scholar]
  18. Sessa C., Goldhirsch A., Martinelli G., Alerci M., Imburgia L., Cavalli F. Phase I study of the combination of monthly carboplatin and weekly cisplatin. Ann Oncol. 1991 Feb;2(2):123–129. doi: 10.1093/oxfordjournals.annonc.a057874. [DOI] [PubMed] [Google Scholar]
  19. Sheiner L. B., Beal S. L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 Aug;9(4):503–512. doi: 10.1007/BF01060893. [DOI] [PubMed] [Google Scholar]
  20. Shemesh O., Golbetz H., Kriss J. P., Myers B. D. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985 Nov;28(5):830–838. doi: 10.1038/ki.1985.205. [DOI] [PubMed] [Google Scholar]
  21. Sokoll L. J., Russell R. M., Sadowski J. A., Morrow F. D. Establishment of creatinine clearance reference values for older women. Clin Chem. 1994 Dec;40(12):2276–2281. [PubMed] [Google Scholar]
  22. Weber J. A., van Zanten A. P. Interferences in current methods for measurements of creatinine. Clin Chem. 1991 May;37(5):695–700. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES